Many providers recommend appointments at 1 month, 3 months, 6 months, and 12 months after discontinuation, with ongoing annual visits thereafter
However, understanding the relationship between dose (mg) and volume (mL) is important for healthcare professionals, particularly when addressing patient questions
Retatrutide's TRIUMPH-4 data is stronger than any obesity drug that has gone through FDA review
Approved incretin labels include special-population guidance, but retatrutide does not yet have approved labeling to guide routine clinical decisions [2], [12], [13]
Combination naltrexone and bupropion this targets brain appetite but is linked to hypertension and seizures, constipation and suicidal thoughts